Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Code Biotherapeutics Inc.
Headquarters: Hatfield, PA, United States of America
Website: https://www.codebiotx.com/
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Oct 22, 2024
Management Tracks
Ray Jupp named CSO at ViaNautis
Plus: Pellegrini joins Kaia and an update from AAVantgarde
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Nov 16, 2022
Management Tracks
Bungay becomes CEO at Imophoron, Garzoni transitions to CSO
Plus: Tracy named CTO at Code, and updates from ConcertAI, Lucy, Trevi and more
BioCentury | Sep 29, 2022
Management Tracks
Kevin Bunker promoted to CSO at Zentalis
Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | Sep 21, 2022
Product Development
How venture philanthropy is driving modality innovation for DMD
Targeted antisense and non-viral gene therapies top CureDuchenne’s technology priority list
BioCentury | Jun 7, 2022
Finance
Code financing puts it in top 10 for 2022 series A rounds
Non-viral gene therapy play raises $75M in deal led by Northpond Ventures
BioCentury | Jun 7, 2022
Data Byte
Top series A rounds of U.S. biotechs year to date
The year has seen 11 U.S. therapeutics developers raise series As of $75M or more, mostly funding new modality platform plays
BioCentury | Feb 23, 2022
Product Development
Feb. 22 Quick Takes: Enhertu meets mark in breast cancer subgroup
Plus updates from BeiGene, Takeda, Code, Kiniksa, Hangzhou, Homology and more
BioCentury | Feb 2, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging companies
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Dec 4, 2021
Management Tracks
Aubuchon becomes CCO at AbCellera
Plus: Albireo, Fore, Code, SomaLogic and more
Items per page:
1 - 10 of 13